Regulatory/Compliance Filing
Rekvina Labs Reports No Fund Use Deviation
Rekvina Labs reported no deviation or variation in the use of ₹46 lakh raised through a preferential issue for working capital and general corporate purposes.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
7
Neutral
2
Bullish
5
Bearish
7
Neutral
2
Bullish
37
Bearish
0
Neutral
0
Bullish
32
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Rekvina Labs Ltd (VINRKLB) is currently trading at 75.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Rekvina Laboratories Limited is an Indian pharmaceutical manufacturer and contract research and manufacturing service provider, incorporated in 1988 and registered as a Public Limited Company in England and Wales; it produces formulations and niche products such as a tissue adhesive (REKSEAL) while focusing on strengthening manufacturing, R&D and regulatory compliance across operations. Recent reported financials show material scale contraction: standalone revenue from operations for Q1FY27 was Rs. 66.85 lakhs and for FY26 was Rs. 126.54 lakhs, a fraction of the historical claim of sales ‘in excess of Rs. 20 crore’, signalling a pronounced decline in turnover and market traction in recent years. Profitability remains weak with the company reporting a standalone quarterly loss of Rs. 12.05 lakhs for the quarter ended 30 June 2026 and an annual loss of Rs. 25.47 lakhs for FY26; basic EPS for the year is negative at Rs. -0.42, reflecting persistent operating losses and cost pressures. Governance and reporting: the Board met on 13 August 2026, approved the Q1 results and appointed Surbhit Shah as Chairman and Executive Director; statutory auditor issued an unmodified limited review, indicating no qualification on the interim financial statements for the quarter reviewed. Strategic emphasis described by management includes a renewed focus on core manufacturing and formulations, accelerated R&D to improve cost competitiveness and regulatory compliance, and cost optimization across operations, which suggests management is prioritising operational turnaround rather than aggressive external expansion or transformational M&A.
Over the past 52 weeks, Rekvina Labs Ltd has traded between a low of ₹6.75 and a high of ₹74.07. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Rekvina Labs Ltd has a market capitalization of approximately 82.33. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Rekvina Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -235.23 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 82.33 Cr, Rekvina Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Rekvina Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Rekvina Labs Ltd is -235.23. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The offer price is ₹10 per fully paid-up equity share, payable in cash.
Regulatory/Compliance Filing
Rekvina Labs reported no deviation or variation in the use of ₹46 lakh raised through a preferential issue for working capital and general corporate purposes.
Financial Results
Rekvina Labs approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, and appointed Bhagyshree Kandoi as Company Secretary and Compliance Officer.
Financial Results
Rekvina Labs Ltd approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, and appointed Bhagyshree Kandoi as Company Secretary and Compliance Officer.
Pharmaceuticals & Biotechnology
Pharmaceuticals
84 Cr
Low Risk
-239.9
39.0
—
21.3
74.07
6.75
Sales CAGR
Profit CAGR
ROE
ROCE